JPRN-UMIN000030328已完成未知
The efficacy of re-challenge of denosumab in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant setting - The efficacy of re-challenge of denosumab in postmenopausal women with hormone receptor-positive breast cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Diagnosis of clinical or radiological disant metastasis before inclusion 2) Invasive bilateral breast cancer 3) Received prior treatment with intravenous bisphosphonates within the past 12 months 4) Following diseases which may interfere with DXA scan such as severe scoliosis, vertebral diseases 5) Current active dental problems including infection of the teeth or jawbone. Recent (within 6 weeks) or planned dental or jaw surgery(e.g., extraction, implants) 6) Other conditions judged as inappropriate for the study by the investigator
研究者
相似试验
已完成
3 期
A randomised, double-blind, placebo controlled trial to examine the effects of total oestradiol depletion on bone microstructure and the efficacy of denosumab in preventing microstructural bone decay in premenopausal women with early breast cancerMetabolic and Endocrine - Other endocrine disordersCancer - BreastMusculoskeletal - Osteoporosisbreast cancerpremenopausal osteoporosisACTRN12616001051437Professor Mathis Grossmann74
已完成
不适用
The prospective study of denosumab for the treatment of osteoporosis in hemodialysis patientsOsteoporosisJPRN-UMIN000022179Yujinkai Medical Corporation Yujin-yamazaki Hospital38
已完成
2 期
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant settingBreast CancerJPRN-UMIN000013863Department of Endocrine and breast cancer, Kyoto Prefectural University of medicine100
已完成
2 期
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant settingbreast cancerJPRN-UMIN000027425Kyoto Prefectural Universuty of Medicine100
进行中（未招募）
1 期
Addition of Denosumab to two different neoadjuvant treatment schedules of nab-PaclitaxelEUCTR2015-001755-72-DEGerman Breast Group778